Description: H.Amdt. 974 — 106th Congress (1999-2000)All Information (Except Text)

As of 08/17/2018 the description for this amendment has not been received.

Purpose:

An amendment numbered 32 printed in the Congressional Record to require, upon FDA approval of a new drug, the disclosure of the taxpayer funded contribution to the total cost of research and development of said drug.

House Amendment Code:

(A035)

House Tally Clerks use this code to manage amendment information.